Entering text into the input field will update the search result below

Acasti Pharma initiates pharmacokinetic bridging study for lead candidate GTX-104

Male Medical Researcher
FatCamera/iStock via Getty Images

  • Acasti Pharma (NASDAQ:ACST) announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects.
  • The PK

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ACST
--
ACST:CA
--